[
  {
    "pmid": "40650712",
    "citation": "Carlos Jim\u00e9nez-Vicente et al. Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.. Annals of hematology (2025 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40650712/",
    "drug": "azacitidine",
    "complete_response": 26.1,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 39.1,
    "progression_free_survival_median": null,
    "overall_survival_median": 8.3,
    "total_patients": 23,
    "cmml_patients": null,
    "supporting_quotes": [
      "The median number of cycles administered was four, with an overall response rate (ORR) of 39.1% and a morphological complete remission (CR) rate of 26.1%.",
      "Median overall survival (OS) was 8.3 months.",
      "Patients who achieved a complete response had a better outcome than the rest of the patients in terms of OS (19.8 months (95%CI: 15.7-NR) vs. 4.2 (95%CI: 1.5-NR), p\u2009=\u20090.01)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reported an overall response rate of 39.1% and a complete response rate of 26.1%. Median overall survival was 8.3 months.  Patients achieving complete response had significantly longer survival (19.8 months) compared to non-responders (4.2 months).  The number of CMML patients was not explicitly stated.",
    "has_efficacy_data": true
  },
  {
    "pmid": "40498375",
    "citation": "Kyriaki Katsiki et al. Comparative Analysis of the TCR Repertoire in Bone Marrow CD8. European journal of immunology (2025 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40498375/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "title_or_abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data on CMML treatment was found in the provided title and abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "40337877",
    "citation": "Meng Chen et al. Rare cases of atraumatic splenic rupture managed conservatively in patients with myeloid neoplasms: a report of two cases and literature review.. Chinese clinical oncology (2025 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40337877/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 2,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Here, we present two case reports involving ASR associated with myeloid neoplasms.",
      "The first patient, suffering from chronic myelomonocytic leukemia (CMML) harboring CBL and ASXL1 mutations, developed ASR shortly after receiving treatment with the hypomethylating agent 5-azacytidine."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study presents two case reports of atraumatic splenic rupture (ASR) in patients with myeloid neoplasms, one of whom had CMML.  No response rates or survival data related to CMML treatment efficacy are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "40252309",
    "citation": "Julie S Braish et al. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome.. Leukemia research (2025 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40252309/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 49.0,
    "progression_free_survival_median": 6.0,
    "overall_survival_median": 7.0,
    "total_patients": 33,
    "cmml_patients": null,
    "supporting_quotes": [
      "The ORR was 49\u202f%, and the median overall survival (OS) was 7 months (95\u202f% CI, 3.5-10.5).",
      "The median progression-free survival (PFS) was 6 months (95\u202f% CI, 3.0-9.0).",
      "This Phase I/II study evaluates the safety, tolerability, and efficacy of venetoclax, an orally bioavailable BCL-2 inhibitor, in combination with azacitidine in this population. We conducted a single-center, dose-escalation, Phase I/II trial (NCT04550442) involving 33 patients with HR-MDS or CMML (IPSS \u2265 1.5) who had progressed after prior HMA therapy."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 49%, with median progression-free survival and overall survival of 6 and 7 months, respectively.  The number of CMML patients specifically was not explicitly stated.",
    "has_efficacy_data": true
  },
  {
    "pmid": "40164584",
    "citation": "Alex Bataller et al. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.. Blood cancer journal (2025 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40164584/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 90.0,
    "progression_free_survival_median": 18.0,
    "overall_survival_median": 24.0,
    "total_patients": 124,
    "cmml_patients": 20,
    "supporting_quotes": [
      "The overall response rate was superior in the DEC-C-Ven cohort (90% vs 64%, P\u2009=\u20090.002).",
      "The median overall survival was 24 and 19 months for the DEC-C-Ven and DEC-C cohorts, respectively (P\u2009=\u20090.89), and the median event-free survival durations were 18 and 10 months (P\u2009=\u20090.026).",
      "The DEC-C and DEC-C-Ven cohorts had 73 and 51 patients respectively, resulting in a total of 124 patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The addition of venetoclax to decitabine-cedazuridine resulted in a significantly higher overall response rate (90% vs 64%) and a longer median progression-free survival (18 months vs 10 months) in patients with MDS or CMML.  Overall survival difference was not statistically significant (24 months vs 19 months).",
    "has_efficacy_data": true
  },
  {
    "pmid": "40013211",
    "citation": "Marwa Mir et al. Pleural Effusion in a Patient With Chronic Myelomonocytic Leukemia Treated With Azacitidine.. Cureus (2025 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40013211/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We report the case of a 66-year-old male with a known medical history of CMML"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The paper presents a single case study of a CMML patient with pleural effusion; no response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "39903257",
    "citation": "Kishan A Bhatt et al. Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia.. Melanoma research (2025 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39903257/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Here, we describe the clinical course of a patient who was diagnosed with concurrent MM and CMML"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "No efficacy data (response rates or survival data) is provided for the single patient described in the case study.  The abstract focuses on the challenges of managing concurrent MM and CMML, rather than presenting quantitative treatment efficacy results.",
    "has_efficacy_data": false
  },
  {
    "pmid": "39759649",
    "citation": "Eren Arslan Davulcu et al. A Case of Chronic Myelomonocytic Leukemia With Recurrent Skin Involvement.. Cureus (2024 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39759649/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "This case study describes a 71-year-old male with high-risk CMML, developing pink-purple skin nodules, which regressed with azacitidine and hydroxyurea treatment.",
      "Despite recurrence, disease control was achieved without transformation to acute leukemia."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The case study reports disease control in a single patient with high-risk CMML and skin nodules following treatment with azacitidine and hydroxyurea. No quantitative efficacy metrics such as response rates or survival data were provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "39477459",
    "citation": "Robert McGrath et al. Chronic myelomonocytic leukaemia causing orbital inflammation.. BMJ case reports (2024 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39477459/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We present a case of acute-onset orbital inflammation with rapidly progressive proptosis, episcleral venous stasis with raised intraocular pressure and loss of vision in a patient with a recent diagnosis of chronic myelomonocytic leukaemia (CMML)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study presents a single case report of a CMML patient with orbital inflammation.  Treatment with intravenous steroids resulted in resolution of the inflammation. Subsequent azacitidine treatment showed good systemic control of CMML with no further orbital inflammation. No quantitative efficacy data (response rates or survival) are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "39024804",
    "citation": "Kaiyue Wang et al. Targeting DNA methyltransferases for cancer therapy.. Bioorganic chemistry (2024 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39024804/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract mentions that Azacytidine and Decitabine are FDA and EMA approved for CMML treatment, but provides no specific efficacy data (response rates or survival data).",
    "has_efficacy_data": false
  },
  {
    "pmid": "38939343",
    "citation": "Krzysztof M\u0105dry et al. No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine-a prospective multicenter study by the Polish Adult Leukemia Group.. Frontiers in oncology (2024)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38939343/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 307,
    "cmml_patients": 22,
    "supporting_quotes": [
      "We collected data on 307 patients",
      "CMML (7.1%)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The study focuses on infection rates and antimicrobial prophylaxis, not on the efficacy of azacitidine treatment in terms of response rates or survival.  Therefore, no response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "38879530",
    "citation": "Theodora Chatzilygeroudi et al. Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML.. Clinical epigenetics (2024 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38879530/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 28,
    "cmml_patients": null,
    "supporting_quotes": [
      "Serial HbF measurements by high-performance liquid chromatography (n\u2009=\u200920) showed induction of HbF only among responders (p\u2009=\u20090.030).",
      "Moreover, HbF increase immediately after the first azacytidine cycle demonstrated prognostic value for progression-free survival (PFS) (p\u2009=\u20090.032, HR\u2009=\u20090.19, CI 0.24-1.63).",
      "Targeted pyrosequencing methodology (n\u2009=\u200928) revealed a strong inverse correlation between the degree of \u03b3-globin gene (HBG2) promoter methylation and baseline HbF levels (p\u2009=\u20090.003, r"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 70,
    "efficacy_summary": "The study shows a correlation between early fetal hemoglobin induction and progression-free survival in azacytidine-treated patients.  However,  no specific response rates or overall survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "38711181",
    "citation": "Mar Garc\u00eda-Garc\u00eda et al. Granulomatous dermatitis in the context of chronic myelomonocytic leukemia: More than just reactive infiltrates. An illustrative case report with literature review.. Journal of cutaneous pathology (2024 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38711181/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The study is a single case report and does not provide quantitative clinical efficacy data such as response rates or survival metrics.",
    "has_efficacy_data": false
  },
  {
    "pmid": "38595873",
    "citation": "Ghadir M Nasreddine et al. Chronic Myelomonocytic Leukemia-Associated Immune Thrombocytopenic Purpura: A Report of a Rare Case and a Review of Literature.. Cureus (2024 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38595873/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Our case report explores the rare coexistence of CMML with immune thrombocytopenic purpura (ITP) in a 63-year-old female patient."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study presents a single case report; therefore, no response rates or survival data are provided.  Azacytidine showed partial efficacy for CMML, but the study focuses primarily on the treatment of the associated ITP.",
    "has_efficacy_data": false
  },
  {
    "pmid": "38387931",
    "citation": "Xiao Li et al. [Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia].. Zhongguo shi yan xue ye xue za zhi (2024 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38387931/",
    "drug": "azacitidine",
    "complete_response": 28.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 80.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 17.4,
    "total_patients": 25,
    "cmml_patients": 25,
    "supporting_quotes": [
      "Among them, 20 patients responded, and 7 patients got complete remission (CR).",
      "All patients with CR were treated with DEC as the basic treatment.",
      "After a median follow-up of 16.4 (9.4-20.5) months, 4 patients with CR progressed to acute myeloid leukemia (AML).",
      "The median overall survival (OS) time of 25 CMML patients was 17.4 months"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an 80% overall response rate with a 28% complete remission rate in 25 CMML patients treated with hypomethylating agents. Median overall survival was 17.4 months.  Progression to AML was observed in some patients achieving CR.",
    "has_efficacy_data": true
  },
  {
    "pmid": "38176221",
    "citation": "Almuth Maria Anni Merz et al. Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.. Cancer treatment reviews (2024 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38176221/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) on CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "38091231",
    "citation": "Kensuke Usuki et al. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).. International journal of hematology (2024 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38091231/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 6568,
    "cmml_patients": 182,
    "supporting_quotes": [
      "From August 2011 to January 2016, we enrolled 6568 patients.",
      "Herein, we report the results for ... CMML (n\u2009=\u2009182).",
      "The estimated overall survival (OS) rate at 5 years were ... 15.0% (8.9-22.7%) for CMML."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study provides overall survival (OS) rate at 5 years for CMML patients (15.0%, with a range of 8.9-22.7%).  No other response rates or survival metrics (e.g., PFS) were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "38003211",
    "citation": "Maria Teresa Bochicchio et al. Germline . International journal of molecular sciences (2023 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38003211/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) were found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "37994196",
    "citation": "Andrew M Brunner et al. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.. American journal of hematology (2024 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37994196/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 70,
    "efficacy_summary": "The study demonstrated durable clinical responses in patients with HR/vHR-MDS, but no specific response rates or survival data for CMML or the overall study population are provided in the abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "37550202",
    "citation": "J Liu et al. [Effect and safety of 10-day decitabine-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation in 31 patients with acute myeloid leukemia/myelodysplastic syndrome].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2023 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37550202/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 31,
    "cmml_patients": null,
    "supporting_quotes": [
      "31 patients with acute myeloid leukemia/myelodysplastic syndrome"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study included 31 patients with AML/MDS, but no efficacy data (response rates or survival data) for CMML or AML/MDS is provided in the abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "37548390",
    "citation": "Lisa Pleyer et al. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.. American journal of hematology (2023 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37548390/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 22.8,
    "total_patients": 1441,
    "cmml_patients": 132,
    "supporting_quotes": [
      "Adjusted median overall survival for patients achieving PB-CR was 22.8 months (95%CI 18.9-26.2) versus 10.4 months (95%CI 9.7-11.2) for those who did not; HR\u2009=\u20090.366 (95%CI 0.303-0.441; p\u2009<\u2009.0001).",
      "1441 patients were included.",
      "CMML (n\u2009=\u2009132; 9.2%),"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a median overall survival of 22.8 months for patients achieving peripheral blood complete remission (PB-CR), compared to 10.4 months for those who did not.  The study included 1441 patients, 132 of whom had CMML.",
    "has_efficacy_data": true
  },
  {
    "pmid": "37546162",
    "citation": "Anwarul Islam An unusual response to 5-azacitidine by a patient with chronic myelomonocytic leukemia.. Clinical case reports (2023 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37546162/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Our report describes a patient with CMML who not only did not respond to a conventional dose of intravenous (IV) therapy with AZA, but showed marked progression of the disease with the leucocyte count rising exponentially while undergoing the aforesaid treatment."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports a single case of CMML where treatment with 5-azacitidine resulted in disease progression, indicating a lack of response.  No response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "37422688",
    "citation": "Nicholas J Short et al. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.. Journal of hematology & oncology (2023 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37422688/",
    "drug": "azacitidine",
    "complete_response": 50.0,
    "partial_response": null,
    "marrow_complete_response": 50.0,
    "overall_response_rate": 75.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 8.1,
    "total_patients": 40,
    "cmml_patients": 8,
    "supporting_quotes": [
      "In the AML cohort, ... the CR/CRi rate was 66% (CR 50%; CRi 16%), and the median overall survival (OS) was 8.1 months.",
      "In the MDS/CMML cohort, ... The overall response rate was 75% (CR 13%; mCR with or without HI 50%; HI 13%).",
      "Forty patients were enrolled (32 with AML and 8 with MDS/CMML)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In the AML cohort, a 50% complete response rate and 8.1-month median overall survival were observed.  The MDS/CMML cohort showed a 75% overall response rate, with 13% complete response and 50% marrow complete response.",
    "has_efficacy_data": true
  },
  {
    "pmid": "37414632",
    "citation": "Vincent Jachiet et al. [Dysimmune manifestations associated with myelodysplastic neoplasms and chronic myelomonocytic leukaemias].. Bulletin du cancer (2023 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37414632/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract does not provide any quantitative data on response rates or survival outcomes for CMML patients treated with any specific therapy.  It mentions that the presence of SIAD does not seem to affect overall survival or the risk of transformation into acute myeloid leukemia, but no specific survival data is given.",
    "has_efficacy_data": false
  },
  {
    "pmid": "37383892",
    "citation": "Lai-Jun Deng et al. Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with . World journal of clinical cases (2023 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37383892/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Here, we report a case of CMML"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study presents a single case report of CMML, thus no response rates or survival data are available.  The patient received azacitidine, programmed cell death protein 1, and platinum-based chemotherapy, resulting in severe myelosuppression and death due to leukocyte stasis and dyspnea.",
    "has_efficacy_data": false
  },
  {
    "pmid": "37083373",
    "citation": "Amer M Zeidan et al. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)\u00a0+\u00a0azacitidine in higher risk MDS and CMML-2.. Future oncology (London, England) (2023 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37083373/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract describes the study design and rationale but does not present any clinical efficacy data (response rates or survival data).",
    "has_efficacy_data": false
  },
  {
    "pmid": "37042080",
    "citation": "Raoul Tibes et al. Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.. Cancer (2023 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37042080/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 62,
    "cmml_patients": null,
    "supporting_quotes": [
      "Sixty-two patients (28 [45%] newly diagnosed) were treated in this study",
      "Out of 21 rrAML patients, two achieved response (one complete response/one morphologic leukemia-free state) with no responses seen in seven r/r MDS/CMML patients.",
      "In newly diagnosed AML/MDS, response was seen in six (three had complete remission, two had morphological leukemia-free status) of 27 patients.",
      "Median overall survival was 26.4 and 4.7\u00a0months for newly diagnosed MDS and AML, respectively."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study showed limited response rates in patients with myeloid neoplasms, including  no response in seven patients with refractory/relapsed MDS/CMML.  Overall survival varied greatly depending on the diagnosis (26.4 months for newly diagnosed MDS vs 4.7 months for newly diagnosed AML). Specific response rates (CR, PR, ORR) for CMML were not reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "36845813",
    "citation": "Shekhar Gurung et al. Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report.. Annals of medicine and surgery (2012) (2023 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36845813/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Herein, the authors report a case of CMML in a 72-year-old male"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "No efficacy data (response rates or survival data) is provided for the treatment of CMML in this single case report.  The paper only describes the diagnosis and planned treatment of one patient.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36801588",
    "citation": "Tugcan Alp Kirkizlar et al. Incidence and predisposing factors of infection in patients treated with hypomethylating agents.. Leukemia research (2023 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36801588/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 7.8,
    "total_patients": 43,
    "cmml_patients": 3,
    "supporting_quotes": [
      "43 adult patients with AML or high-risk MDS or CMML who received HMA \u2265 2 consecutive cycles from January 2014 to December 2020 were enrolled in the study.",
      "CMML in 3 patients (7 %)",
      "The median survival was 7.8 months in non-infected cycles while 6.83 months in infected cycles."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a median overall survival of 7.8 months in non-infected cycles and 6.83 months in infected cycles.  No response rates were reported.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36517990",
    "citation": "Sarit Assouline et al. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.. Leukemia & lymphoma (2023 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36517990/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data for CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36506761",
    "citation": "Jorgena Kosti et al. Extramedullary Myeloid Leukemia in the Setting of a Myeloproliferative Neoplasm.. Journal of medical cases (2022 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36506761/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data on CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36455187",
    "citation": "Raphael Itzykson et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36455187/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 170,
    "cmml_patients": null,
    "supporting_quotes": [
      "One-hundred seventy patients received DAC (n = 84) or HY (n = 86).",
      "Compared with HY, frontline treatment with DAC did not improve EFS in patients with advanced myeloproliferative CMML"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The study found no improvement in progression-free survival (EFS) with decitabine compared to hydroxyurea in patients with advanced myeloproliferative CMML.  No response rates or overall survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36282401",
    "citation": "Julia Reiser et al. Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.. Wiener medizinische Wochenschrift (1946) (2023 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36282401/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 23.0,
    "total_patients": 168,
    "cmml_patients": 168,
    "supporting_quotes": [
      "In a retrospective observational study, we analyzed 168 CMML patients regarding treatment options and survival during the past three decades.",
      "Median overall survival (OS) increased from 10 months before 2000 to 23 months thereafter (p\u202f= 0.021).",
      "AZA-treated patients but not patients treated with other treatment options had improved survival as compared to CMML patients without AZA therapy (19 vs. 25 months, p = 0.041)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an increase in median overall survival from 10 months to 23 months over three decades.  Azacitidine (AZA) treatment was associated with improved survival (19 vs 25 months), particularly in subgroups with Hb >10 g/dL, monocytosis >10 G/L, and RASopathy gene mutations.",
    "has_efficacy_data": true
  },
  {
    "pmid": "36153475",
    "citation": "Tamara K Moyo et al. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated\u00a0active myeloid target compound combinations in MDS/MPN overlap syndromes.. BMC cancer (2022 Sep)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36153475/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract describes the study design and objectives but does not present any clinical efficacy data such as response rates or survival data.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36150563",
    "citation": "Faezeh Darbaniyan et al. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.. Experimental hematology (2022 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36150563/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival metrics) were found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36104395",
    "citation": "Arsene Mekinian et al. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.. Leukemia (2022 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36104395/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data on CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "36059252",
    "citation": "Yue Wei et al. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.. Leukemia & lymphoma (2022 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36059252/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data)  was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "35852697",
    "citation": "Takeshi Hagino et al. Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia.. International journal of hematology (2022 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35852697/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We herein report the case of an 80-year-old Japanese man with chronic myelomonocytic leukemia (CMML)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The provided abstract describes a single case study of a CMML patient; therefore, no response rates or survival data are available.",
    "has_efficacy_data": false
  },
  {
    "pmid": "35834039",
    "citation": "Yu Xu et al. Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.. Investigational new drugs (2022 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35834039/",
    "drug": "azacitidine",
    "complete_response": 8.3,
    "partial_response": 8.3,
    "marrow_complete_response": 20.8,
    "overall_response_rate": 37.5,
    "progression_free_survival_median": null,
    "overall_survival_median": 23.0,
    "total_patients": 24,
    "cmml_patients": 24,
    "supporting_quotes": [
      "Overall response rate (ORR) was 37.5% (9 of 24); CR rate, PR rate, and mCR/HI rate were 8.3% (n\u2009=\u20092), 8.3% (n\u2009=\u20092), and 20.8% (n\u2009=\u20095), respectively.",
      "At a median duration of follow-up of 14.0\u00a0months (range 0.0-22.0\u00a0months), the median overall survival (OS) was 23.0\u00a0months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Azacitidine treatment showed an overall response rate of 37.5% in a study of 24 CMML patients.  Complete response, partial response, and marrow complete response rates were 8.3%, 8.3%, and 20.8%, respectively. Median overall survival was 23 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "35707788",
    "citation": "Xinhui Zheng et al. Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis.. Global medical genetics (2022 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35707788/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No efficacy data (response rates or survival metrics) were present in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "35615323",
    "citation": "Antonio Cristiano et al. The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19.. Mediterranean journal of hematology and infectious diseases (2022)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35615323/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Here, we describe the molecular profile of a patient with AML rapidly evolved from a previous therapy-related-Chronic MyeloMonocytic Leukemia, who achieved safely complete remission after treatment with the VEN/Azacitidine combination, even in the presence of SARS-COVID-2 infection."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study describes a single case of AML that evolved from CMML achieving complete remission after treatment with Venetoclax/Azacitidine.  No overall response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "35488900",
    "citation": "Mikkael A Sekeres et al. A phase 1b study of glasdegib\u2009+\u2009azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.. Annals of hematology (2022 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35488900/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 33.3,
    "progression_free_survival_median": null,
    "overall_survival_median": 15.8,
    "total_patients": 72,
    "cmml_patients": null,
    "supporting_quotes": [
      "Overall response rates in the AML and MDS cohorts were 30.0% and 33.3%, respectively",
      "Median overall survival (95% confidence interval) was 9.2 (6.2-14.0) months and 15.8 (9.3-21.9) months, respectively"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 33.3% in the MDS cohort (which includes CMML patients), and a median overall survival of 15.8 months in the same cohort.  The exact number of CMML patients is not specified.",
    "has_efficacy_data": true
  },
  {
    "pmid": "35438802",
    "citation": "Lionel Ad\u00e8s et al. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's \"pick a winner\" trial, with the impact of somatic mutations.. British journal of haematology (2022 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35438802/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 21.4,
    "progression_free_survival_median": 17.2,
    "overall_survival_median": 19.7,
    "total_patients": 322,
    "cmml_patients": null,
    "supporting_quotes": [
      "After six cycles, 69 (21.4%) CR\u2009+\u2009PR were observed with no benefit from any combination.",
      "Median EFS and OS were 17.2 and 19.7 months in the whole cohort, respectively, with no difference across randomised arms.",
      "322 patients were included."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 21.4% after six cycles of treatment.  Median progression-free survival was 17.2 months, and median overall survival was 19.7 months. No significant benefit was observed from any combination therapy compared to azacitidine alone.",
    "has_efficacy_data": true
  },
  {
    "pmid": "35405632",
    "citation": "A Triguero et al. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.. Leukemia research (2022 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35405632/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 58.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 91,
    "cmml_patients": 91,
    "supporting_quotes": [
      "The overall response rate at cycle 4-6 was 58%",
      "We retrospectively studied 91 patients with CMML treated with at least one cycle of AZA from the Spanish Registry of MDS."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study shows an overall response rate of 58% at cycles 4-6 in 91 CMML patients treated with azacitidine.  No data on complete response, partial response, marrow complete response, progression-free survival, or overall survival was provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34985762",
    "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.. American journal of hematology (2022 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34985762/",
    "drug": "azacitidine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 47.5,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ~40%-50% and complete remission rates of ~7%-17%; with no impact on mutational allele burdens."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The abstract reports overall response rates of approximately 47.5% (midpoint of 40-50%) for hypomethylating agents like 5-azacitidine and decitabine, and complete remission rates of approximately 7-17%.  No survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34966690",
    "citation": "Konstantinos Liapis et al. Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?. Frontiers in oncology (2021)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34966690/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract does not contain any specific clinical efficacy data (response rates or survival data) for CMML treatments.",
    "has_efficacy_data": false
  },
  {
    "pmid": "34884286",
    "citation": "Marion Delplanque et al. USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still's Disease in Elderly Patients.. Journal of clinical medicine (2021 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34884286/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 83.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 30.0,
    "total_patients": 26,
    "cmml_patients": null,
    "supporting_quotes": [
      "A French multicenter retrospective study from the MINHEMON study group also used for other published works with the support of multidisciplinary and complementary networks of physicians and a control group of 104 MDS/CMML. Twenty-six patients were included with a median age at first signs of USAID of 70.5 years with male predominance (4:1).",
      "Azacytidine resulted in complete or partial response in systemic symptoms for 10/12 (83%) patients including 3 VEXAS.",
      "Twelve died during a median follow-up of 2.5 years"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 85,
    "efficacy_summary": "The study reports an 83% overall response rate to azacytidine for systemic symptoms in 10 out of 12 patients.  The median overall survival was 30 months (2.5 years).  Specific response rates (complete, partial, marrow complete) were not reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34789825",
    "citation": "Mikkael A Sekeres et al. Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.. Leukemia (2021 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34789825/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "34384334",
    "citation": "Krzysztof M\u0105dry et al. Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PolAZA'.. Hematology (Amsterdam, Netherlands) (2021 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34384334/",
    "drug": "azacitidine",
    "complete_response": 20.0,
    "partial_response": 12.0,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 15.0,
    "total_patients": 315,
    "cmml_patients": null,
    "supporting_quotes": [
      "Complete remission (CR) was obtained in 20% and partial remission (PR) in 12% of patients.",
      "Median survival was 15 (13-19) months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a 20% complete response rate and a 12% partial response rate to azacitidine treatment. Median overall survival was 15 months.  The exact number of CMML patients within the study cohort is not specified.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34268023",
    "citation": "Jay Pescatore et al. Reactivation of Pulmonary Tuberculosis During Treatment of Chronic Myelomonocytic Leukemia.. Cureus (2021 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34268023/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 76-year-old woman from a tuberculosis (TB) endemic region with chronic myelomonocytic leukemia (CMML) on Azacitidine presented with a non-productive cough."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study only describes a single case of a 76-year-old woman with CMML and does not provide any clinical efficacy data such as response rates or survival metrics.",
    "has_efficacy_data": false
  },
  {
    "pmid": "34194799",
    "citation": "Soichiro Nakako et al. Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil.. Clinical case reports (2021 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34194799/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 55-year-old man was diagnosed with therapy-related chronic myelomonocytic leukemia (t-CMML) after exposure to tegafur/gimeracil/oteracil.",
      "Although he was refractory to hydroxyurea and low-dose cytarabine, combination therapy with cytarabine, aclarubicin and azacitidine (CA-AZA) provided good disease control, and he underwent allogeneic stem cell transplantation."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study involved a single patient with t-CMML who achieved good disease control with CA-AZA therapy after being refractory to other treatments. No quantitative response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "34175902",
    "citation": "Aline Renneville et al. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.. Leukemia (2021 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34175902/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 24.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Median overall survival of this aggressive myeloid malignancy is only 2-3 years"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract mentions a median overall survival of 2-3 years (24-36 months).  No other response rates or survival data are explicitly provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33904891",
    "citation": "Anand A Patel et al. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.. Blood advances (2021 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33904891/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract mentions FDA approval of C-DEC for CMML based on phase 2 and 3 trials showing bioequivalence to parenteral decitabine, but provides no specific efficacy metrics (response rates or survival data).",
    "has_efficacy_data": false
  },
  {
    "pmid": "33807279",
    "citation": "Jan Philipp Bewersdorf et al. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).. Cancers (2021 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33807279/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract provides background information on MDS and CMML treatment but does not contain any specific efficacy data such as response rates or survival times for any treatment.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33709786",
    "citation": "Swapna Thota et al. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.. Future oncology (London, England) (2021 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33709786/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract does not provide specific clinical efficacy metrics like response rates or survival data for CMML patients treated with C-DEC.  The text focuses on the drug's development and approval, mentioning its comparison to existing treatments but not providing quantitative results from clinical trials.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33706667",
    "citation": "Ruohao Xu et al. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.. Hematology (Amsterdam, Netherlands) (2021 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33706667/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 43.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 600,
    "cmml_patients": 600,
    "supporting_quotes": [
      "HMAs yielded a pooled ORR estimate of 43% (95% CI: 36%-50%) in patients with CMML.",
      "Fourteen studies with 600 CMML patients (decitabine: n=196; azacitidine: n=404) were identified and included for meta-analysis.",
      "Patients received either azacitidine or decitabine exhibited comparable incidence of ORR (43% vs. 45%, P=0.810), while significantly higher incidence of mCR was observed in patients treated with decitabine (23% vs. 10%, P=0.000)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The meta-analysis of 600 CMML patients treated with hypomethylating agents (HMAs) showed an overall response rate (ORR) of 43%.  Decitabine showed a higher marrow complete response (mCR) rate (23%) compared to azacitidine (10%).  ORR was comparable between the two drugs.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33513373",
    "citation": "Lisa Pleyer et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.. The Lancet. Haematology (2021 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33513373/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 20.7,
    "total_patients": 949,
    "cmml_patients": 949,
    "supporting_quotes": [
      "Adjusted median overall survival for patients treated with hydroxyurea versus hypomethylating agents was 15\u00b76 months (95% CI 13\u00b71-17\u00b73) versus 20\u00b77 months (17\u00b79-23\u00b74); hazard ratio (HR) 1\u00b739 (1\u00b717-1\u00b765; p=0\u00b70002)",
      "412 (43%) of 949 patients received hypomethylating agents as first treatment, 391 (41%) hydroxyurea, and 83 (9%) intensive chemotherapy."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a median overall survival of 20.7 months for patients treated with hypomethylating agents, compared to 15.6 months for those treated with hydroxyurea.  Hypomethylating agents showed a survival advantage over hydroxyurea and intensive chemotherapy, particularly in higher-risk CMML patients and those with myeloproliferative CMML.  No response rates were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33503305",
    "citation": "Xiaofei Zhou et al. Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.. Clinical and translational science (2021 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33503305/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 450,
    "cmml_patients": null,
    "supporting_quotes": [
      "A sample size of ~ 30 East Asian patients (of ~ 450 randomized) was estimated as needed to demonstrate consistency in efficacy relative to the global population."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study focuses on the design and rationale of a Phase 3 clinical trial (PANTHER) involving pevonedistat in combination with azacitidine for higher-risk MDS, higher-risk CMML, and low-blast AML.  No specific efficacy data (response rates or survival data) from this trial are presented in the abstract. The total number of patients in the PANTHER trial is estimated at 450, with approximately 30 from East Asia.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33483617",
    "citation": "Mikkael A Sekeres et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.. Leukemia (2021 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33483617/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data on CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33407852",
    "citation": "Johannes Lorenz Berg et al. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.. Clinical epigenetics (2021 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33407852/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract does not contain any clinical efficacy data (response rates or survival data). The study focuses on the molecular mechanisms of action of hypomethylating agents in CMML, not on the clinical outcomes.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33369023",
    "citation": "John C Molina et al. Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.. Pediatric blood & cancer (2021 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33369023/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We describe an adolescent with monosomy 7 CMML"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study describes a single case of CMML treated with venetoclax and decitabine as a bridge to HSCT.  The abstract states that the treatment was 'effective' but provides no quantitative efficacy data.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33324479",
    "citation": "Luka \u010cema\u017ear et al. Successful long-term treatment with azacitidine in patient with chronic myelomonocytic leukemia.. Hematology reports (2020 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33324479/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 137.0,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Effective treatment with azacitidine resulted in overall survival of 11 years 5 months",
      "Our report about a patient with CMML and a good clinical course revealed, that long term treatment with azacitidine is feasible in some patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a single case of CMML successfully treated with azacitidine resulting in an overall survival of 137 months (11 years and 5 months).  No other response rates or survival metrics are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33280448",
    "citation": "Jorge Ramos Perez et al. Emerging drugs for the treatment of chronic myelomonocytic leukemia.. Expert opinion on emerging drugs (2020 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33280448/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival metrics) were found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33275673",
    "citation": "Mrinal M Patnaik et al. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.. Hematology. American Society of Hematology. Education Program (2020 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33275673/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 45.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 36.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "CMML usually presents in the 7th decade of life, with a male preponderance and is associated with a median overall survival of <36 months.",
      "Hypomethylating agents such as azacitidine, decitabine and oral decitabine/cedazuridine have been US FDA approved for the management of CMML, with overall response rates of 40-50% and complete remission rates of <20%."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The median overall survival for CMML is less than 36 months.  Overall response rates to hypomethylating agents (azacitidine, decitabine, and oral decitabine/cedazuridine) are 40-50%, with complete remission rates less than 20%.  No data on progression-free survival,  patient numbers, or complete/partial response rates were explicitly stated.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33126392",
    "citation": "Lianbo Hu et al. Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report.. Medicine (2020 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33126392/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Here we reported a rare case of CMML-0 with pleural effusion as the first manifestation in a 44-year-old woman.",
      "The patient was treated with azacitidine 75\u200amg/m\u200ad for 2 cycles, followed by daily oral intake of hydroxyurea (500\u200amg/d). Pleural effusion was resolved and chest pain was relieved."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The case report describes a single patient with CMML-0 and pleural effusion who achieved resolution of pleural effusion and chest pain after treatment with azacitidine and hydroxyurea.  No quantitative response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33101773",
    "citation": "Ana Mar\u00eda Hurtado L\u00f3pez et al. Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach.. Oncoimmunology (2020 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33101773/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) were found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "33043739",
    "citation": "C Willekens et al. Effects of azacitidine in 93 patients with . Leukemia & lymphoma (2021 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33043739/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 93,
    "cmml_patients": null,
    "supporting_quotes": [
      "Effects of azacitidine in 93 patients with"
    ],
    "data_source_location": "title_or_abstract",
    "extraction_confidence": 50,
    "efficacy_summary": "The provided abstract only mentions the total number of patients (93) in the study, but does not contain any efficacy data regarding CMML treatment response rates or survival metrics.",
    "has_efficacy_data": false
  },
  {
    "pmid": "32896704",
    "citation": "Anne Laure Roupie et al. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.. Seminars in arthritis and rheumatism (2020 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32896704/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 44.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 70,
    "cmml_patients": null,
    "supporting_quotes": [
      "After a median follow-up of 33.2 months [1-162], 31 patients (44%) achieved sustained remission."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a 44% sustained remission rate after a median follow-up of 33.2 months.  No other response rates or survival data (PFS, OS) were explicitly provided.  Conventional DMARDs showed lower efficacy compared to biologics or azacytidine.",
    "has_efficacy_data": true
  },
  {
    "pmid": "32860582",
    "citation": "Sohita Dhillon Decitabine/Cedazuridine: First Approval.. Drugs (2020 Sep)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32860582/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data for CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "32576961",
    "citation": "Arnold Kloos et al. Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.. Leukemia (2020 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32576961/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "The novel combination treatment with azacitidine and the MEK-inhibitor trametinib additively inhibited ERK-phosphorylation and thus depleted the signal from mutated NRAS.",
      "The combination treatment significantly prolonged survival of CMML mice compared to single-agent treatment."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study demonstrates that the combination treatment of azacitidine and trametinib significantly prolonged survival in a CMML mouse model.  However, no specific response rates or survival metrics (in months) are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "32442785",
    "citation": "Shyamala C Navada et al. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.. Leukemia research (2020 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32442785/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 18,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Phase 1 results from a Phase 1/2 study comprise 18 patients with myelodysplastic syndromes (MDS; n = 9), acute myeloid leukemia (AML; n = 8), and chronic myelomonocytic leukemia (CMML; n = 1)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The abstract only provides the number of patients with CMML (1 out of 18 total) and does not report any response rates or survival data.",
    "has_efficacy_data": false
  },
  {
    "pmid": "32373459",
    "citation": "Celine Berthon et al. Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size.. Leukemia research reports (2020)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32373459/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": 40,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 0,
    "supporting_quotes": [
      "Both diseases first responded to treatment for 40 months after 7+3 induction and maintenance therapy of azacytidine + lenalidomide.",
      "MM relapsed first and was treated with azacytidine + daratumumab, which led an additional 15 months of progression-free survival."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a single case of synchronous AML and MM.  Initial treatment with azacytidine + lenalidomide resulted in 40 months of response for both diseases. Following MM relapse, treatment with azacytidine + daratumumab provided an additional 15 months of progression-free survival.  No response rates were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "32285126",
    "citation": "Guillermo Garcia-Manero et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.. Blood (2020 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32285126/",
    "drug": "azacitidine",
    "complete_response": 21.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 60.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 80,
    "cmml_patients": null,
    "supporting_quotes": [
      "Clinical responses were observed in 48 patients (60%), including 17 (21%) with complete response."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reported an overall response rate of 60%, with a complete response rate of 21%.  No partial response, marrow complete response, progression-free survival, or overall survival data were provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31870430",
    "citation": "Anastasiya Kazachenka et al. Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.. Genome medicine (2019 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31870430/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 50.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Drugs that reverse epigenetic repression, such as 5-azacytidine (5-AZA), induce haematological improvement in half of treated patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study mentions that 5-azacytidine induces hematological improvement in 50% of treated patients.  No other response rates or survival data are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31736132",
    "citation": "Mrinal M Patnaik et al. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.. American journal of hematology (2020 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31736132/",
    "drug": "azacitidine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 45.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ~40%-50% and complete remission rates of ~7%-17%; with no impact on mutational allele burdens."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The abstract reports overall response rates of 40-50% and complete remission rates of 7-17% for hypomethylating agents in CMML treatment.  No other efficacy data such as survival times or patient numbers are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31645386",
    "citation": "M Mansour Ceesay et al. Intractable pruritus in chronic myelomonocytic leukaemia and myelodysplastic syndromes: a case series.. BMJ case reports (2019 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31645386/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 4,
    "cmml_patients": 2,
    "supporting_quotes": [
      "We present two cases of CMML and two cases of MDS with this challenging symptom."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports on four patients (two with CMML, two with MDS) with intractable pruritus.  No quantitative efficacy data on treatment response or survival is provided.  One CMML patient achieved morphological remission with azacitidine, and another had a complete response to cladribine for pruritus, but these are anecdotal and not response rates.",
    "has_efficacy_data": false
  },
  {
    "pmid": "31559392",
    "citation": "Abhishek A Mangaonkar et al. Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics.. Advances in cell and gene therapy (2019 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31559392/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 24.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Outcomes remain uniformly poor with a median overall survival of ~2 years"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The abstract mentions a median overall survival of approximately 2 years (24 months).  No other efficacy data such as response rates or progression-free survival is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31506740",
    "citation": "Anja L Gawlitza et al. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.. Journal of cancer research and clinical oncology (2019 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31506740/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 15,
    "cmml_patients": null,
    "supporting_quotes": [
      "Using next-generation sequencing (NGS), 30 myeloid leukemia-associated genes were analyzed in 15 MDS/CMML patients with excellent response to Aza."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The study mentions 15 MDS/CMML patients with excellent response to Aza, but does not provide specific response rates or survival data.  The focus is on the molecular mechanisms of response, specifically demethylation of EZH2 and NOTCH1.",
    "has_efficacy_data": false
  },
  {
    "pmid": "31494229",
    "citation": "Yi-Geng Cao et al. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2020 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31494229/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 48,
    "cmml_patients": 4,
    "supporting_quotes": [
      "A total of 48 patients were enrolled, including 44 with MDS and 4 with chronic myelomonocytic leukemia (CMML)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The provided text only gives the total number of patients enrolled in the study and the number of patients with CMML.  No response rates or survival data are reported.",
    "has_efficacy_data": false
  },
  {
    "pmid": "31484886",
    "citation": "Shin Ohara et al. [Impact of time to hematological response on survival in patients treated with azacytidine: a single-center retrospective study].. [Rinsho ketsueki] The Japanese journal of clinical hematology (2019)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31484886/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 95,
    "cmml_patients": 8,
    "supporting_quotes": [
      "We analyzed 95 cases of MDS (n=78), CMML (n=8) and AML (n=9) with blast counts of <30%, treated by AZA since March 2011"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study analyzed overall survival (OS) in patients with MDS, CMML, and AML treated with azacytidine.  While OS differences were observed between response categories (early response, late response, stable disease), specific response rates or median survival times were not provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "31340618",
    "citation": "X L Zhao et al. [Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2019 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31340618/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data on CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "31221030",
    "citation": "Chutima Kunacheewa et al. A systematic review and meta. Hematology (Amsterdam, Netherlands) (2019 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31221030/",
    "drug": "azacitidine",
    "complete_response": 33.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 406,
    "cmml_patients": null,
    "supporting_quotes": [
      "The pooled CR rate after the treatment with AZA-plus-LEN regimen was 33.0% (95% CI, 27.7%-38.7%, I",
      "A total of 10 studies with 406 patients were identified and included into the meta-analysis."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The meta-analysis of 10 studies (406 patients) showed a pooled complete response rate of 33.0% for the AZA-plus-LEN regimen.  No other response rates or survival data were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "30964202",
    "citation": "Tucker Coston et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.. American journal of hematology (2019 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30964202/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 41.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 31.0,
    "total_patients": 121,
    "cmml_patients": 121,
    "supporting_quotes": [
      "The overall response rates were 41% by the IWG MDS (AZA- 45%, DAC-39%), and 56% by the IWG MDS/MPN (AZA-56%, DAC-58%) response criteria, with CR (complete remission) rates of <20% for both agents, by both criteria.",
      "HMA treated patients had a longer median OS (31 vs 18 months; P = .01), in comparison to those treated with conventional care regimens (excluding observation only patients), without any differences between AZA vs DAC (P = .37)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Overall response rates to hypomethylating agents (HMAs) in CMML patients were 41% (IWG MDS criteria) and 56% (IWG MDS/MPN criteria). Complete response rates were less than 20%. Median overall survival was 31 months for patients treated with HMAs, compared to 18 months for those treated with conventional care.  Progression after HMA response was associated with a median overall survival of 8 months, while median OS in patients with primary HMA failure was 4 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "30944097",
    "citation": "Yoshihiro Hayashi et al. NUP98-HBO1-fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis.. Blood advances (2019 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30944097/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data such as response rates or survival metrics were reported in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30937199",
    "citation": "Takeshi Araki et al. A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia.. Case reports in hematology (2019)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30937199/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 67-year-old male, with a known diagnosis of myelodysplastic syndromes with multilineage dysplasia (MDS-MLD) was admitted to our hospital"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The paper presents a single case study of a patient with MDS-MLD who developed acquired haemophilia A. No response rates or survival data related to CMML treatment are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30898482",
    "citation": "Krzysztof M\u0105dry et al. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.. Clinical lymphoma, myeloma & leukemia (2019 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30898482/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 298,
    "cmml_patients": null,
    "supporting_quotes": [
      "We performed a retrospective evaluation of 298 MDS/CMML/AML patients and included in the analysis 232 patients who completed the first 3 cycles of azacitidine therapy or developed Grade III/IV infection before completing the third cycle.",
      "Overall, 143 patients (62%) experienced serious infection, and in 94 patients (41%) infection occurred within the first 3 cycles."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study focuses on infection risk in patients with MDS, CMML, and AML treated with azacitidine.  It reports the total number of patients but does not provide response rates or survival data.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30626790",
    "citation": "Shinichiro Sukegawa et al. [Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine].. [Rinsho ketsueki] The Japanese journal of clinical hematology (2018)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30626790/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Approximately 10%-20% of BPDCN patients develop other hematologic malignancies, including chronic myelomonocytic leukemia (CMML).",
      "Here, we report a BPDCN patient with skin lesions, bone marrow infiltration, and lymphadenopathy. CMML also developed during the course of BPDCN. Azacitidine had positive effects on CMML; however, BPDCN aggressively relapsed during treatment."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The study reports a single case of a BPDCN patient who also developed CMML. Azacitidine showed positive effects on the CMML, but the BPDCN relapsed. No quantitative efficacy data (response rates or survival) are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30613922",
    "citation": "Grzegorz Helbig et al. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.. Pathology oncology research : POR (2019 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30613922/",
    "drug": "azacitidine",
    "complete_response": 10.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 20.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 83,
    "cmml_patients": 10,
    "supporting_quotes": [
      "Complete remission (CR) was achieved in 14% of MDS, 7% of AML and 10% of CMML patients.",
      "Overall response rate was following: 27% for MDS, 20% for AML and 20% for CMML.",
      "The study included 83 patients (65% male) with a median age at diagnosis of 68 years. 43 patients were diagnosed with higher-risk MDS, 30 had AML and 10-CMML."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine showed limited efficacy in CMML patients with a 10% complete response rate and a 20% overall response rate.  Overall survival at 12 months was 75%.  Median follow-up was 9.4 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "30579366",
    "citation": "Paola Orsini et al. Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.. Diagnostic pathology (2018 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30579366/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 46,
    "cmml_patients": 9,
    "supporting_quotes": [
      "Forty-six patients with hematological neoplasms were included in the study: 30 patients affected by chronic lymphocytic leukemia, 7 patients with myelodysplastic syndromes at intermediate/high risk, and 9 patients with myelomonocytic leukemia."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study did not report response rates or survival data.  It only reported the number of patients with CMML and the observation of decreased Alu methylation levels in some CMML patients with a specific gene mutation.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30424699",
    "citation": "Panagiotis T Diamantopoulos et al. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.. Leukemia & lymphoma (2019 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30424699/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 48.9,
    "progression_free_survival_median": null,
    "overall_survival_median": 29.7,
    "total_patients": 88,
    "cmml_patients": 88,
    "supporting_quotes": [
      "The overall response rate was 48.9% and the median overall survival (OS) 29.7 months.",
      "We analyzed the characteristics of 88 patients with CMML homogeneously treated with 5-azacytidine (Hellenic 5-Azacytidine Registry)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study shows an overall response rate of 48.9% and a median overall survival of 29.7 months in 88 CMML patients treated with 5-azacytidine.",
    "has_efficacy_data": true
  },
  {
    "pmid": "30367269",
    "citation": "Anthony M Hunter et al. Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.. Current treatment options in oncology (2018 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30367269/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract does not contain any specific clinical efficacy metrics (response rates or survival data) for CMML treatments.  The paper discusses treatment strategies but doesn't provide quantifiable results.",
    "has_efficacy_data": false
  },
  {
    "pmid": "30091166",
    "citation": "J\u00fcrgen Wehmeyer et al. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).. European journal of haematology (2018 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30091166/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 45.9,
    "progression_free_survival_median": 10.9,
    "overall_survival_median": 14.1,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "45.9% of patients showed CR or PR.",
      "Median PFS was 10.9 months.",
      "Median OS was 14.1 months.",
      "61.1% of patients were diagnosed with MDS, 31.5% with AML and 7.4% with CMML."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In the PIAZA study, azacitidine treatment resulted in a 45.9% overall response rate (CR/PR). Median progression-free survival was 10.9 months, and median overall survival was 14.1 months.  The study did not provide separate CR and PR rates, nor the total number of patients or the number of CMML patients.",
    "has_efficacy_data": true
  },
  {
    "pmid": "30016552",
    "citation": "Michael R Savona et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.. American journal of hematology (2018 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30016552/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 32.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 31,
    "cmml_patients": 4,
    "supporting_quotes": [
      "Overall response rate (complete remission [CR], CR with incomplete hematological recovery [CRi], partial remission [PR], marrow CR) in the MDS/CMML subgroups was 32% and in the AML subgroup (CR/CRi/PR) was 22%",
      "After a pharmacokinetic assessment period, 31 patients (MDS n = 18, CMML n = 4, and AML n = 9) entered a clinical phase"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 32% in the MDS/CMML patient subgroup.  No breakdown of individual response rates (CR, PR, mCR) was provided for the CMML patients specifically, only the combined MDS/CMML group.",
    "has_efficacy_data": true
  },
  {
    "pmid": "29878489",
    "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.. American journal of hematology (2018 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29878489/",
    "drug": "azacitidine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 35.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of \u223c30%-40% and complete remission rates of \u223c7%-17%; with no impact on mutational allele burdens."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "Hypomethylating agents such as 5-azacitidine and decitabine show an overall response rate of approximately 35% (median of the provided range), with a complete remission rate of approximately 7-17%.  No survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "29728305",
    "citation": "Matthieu Duchmann et al. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.. EBioMedicine (2018 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29728305/",
    "drug": "azacitidine",
    "complete_response": 17.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 52.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 174,
    "cmml_patients": 174,
    "supporting_quotes": [
      "Overall response rate (ORR) was 52%, including complete response (CR) in 28 patients (17%)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reported an overall response rate of 52% with a complete response rate of 17% in a cohort of 174 CMML patients treated with hypomethylating agents.  No data on partial response, marrow complete response, progression-free survival, or overall survival was provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "29658352",
    "citation": "Anne-Laure Bernat et al. Chronic subdural collection overlying an intra-axial hemorrhagic lesion in chronic myelomonocytic leukemia: special report and review of the literature.. Expert review of neurotherapeutics (2018 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29658352/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) for CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "29475821",
    "citation": "Jill A Bell et al. Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.. Clinical lymphoma, myeloma & leukemia (2018 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29475821/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Studies showed that HR-MDS/CMML patients treated with a conventional chemotherapy regimen (CCR) have poorer overall survival (OS).",
      "Key findings from individual HR-MDS studies showed improved survival with azacitidine over CCRs and higher overall response rates with clofarabine relative to low-dose cytosine arabinoside (but no significant difference in 2-year OS favoring clofarabine).",
      "OS was highest for patients treated with allo-HSCT."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 70,
    "efficacy_summary": "The study mentions improved survival with azacitidine compared to conventional chemotherapy regimens (CCRs) in HR-MDS patients and higher overall response rates with clofarabine versus low-dose cytosine arabinoside, but no specific numerical data on response rates or survival times (in months) is provided.  Overall survival was reported as highest in patients receiving allo-HSCT, but the median OS is not stated.  The abstract focuses more on qualitative comparisons of treatment effectiveness.",
    "has_efficacy_data": false
  },
  {
    "pmid": "29384408",
    "citation": "Kathrin Thomay et al. Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy.. Leukemia & lymphoma (2018 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29384408/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [],
    "data_source_location": "title_and_abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study involves only one patient with CMML who progressed to secondary AML.  No efficacy data related to CMML treatment is presented.",
    "has_efficacy_data": false
  },
  {
    "pmid": "29383443",
    "citation": "Florian Huemer et al. Establishment and validation of a\u00a0novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.. Wiener klinische Wochenschrift (2018 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29383443/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 120,
    "cmml_patients": 120,
    "supporting_quotes": [
      "In multivariate analysis we identified elevated lactate dehydrogenase (\u2265223\u202fU/l), higher bone marrow blast percentage (\u22657.5%) and thrombocytopenia (<55\u202fG/l) at initial diagnosis as the most relevant parameters for the time to first treatment.",
      "In the high-risk group (\u22652\u00a0risk factors) 85% of patients required treatment within 1\u00a0year, whereas this was the case in 48% in the intermediate-risk (1\u00a0risk factor) and in 0% in the low-risk group (0\u00a0risk factors).",
      "We tested clinical parameters and cytogenetic information for their ability to predict the time to first treatment in our single center cohort of 55 unselected consecutive chronic myelomonocytic leukaemia patients.  In the high-risk group (\u22652\u00a0risk factors) 85% of patients required treatment within 1\u00a0year, whereas this was the case in 48% in the intermediate-risk (1\u00a0risk factor) and in 0% in the low-risk group (0\u00a0risk factors)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study focuses on predicting time to first treatment (azacitidine or hydroxyurea) in CMML patients, not on treatment efficacy metrics like response rates or survival.  A risk model based on lactate dehydrogenase levels, bone marrow blast percentage, and thrombocytopenia is developed and validated.  The model predicts that 85% of high-risk patients require treatment within one year, compared to 48% and 0% in intermediate and low-risk groups, respectively.",
    "has_efficacy_data": false
  },
  {
    "pmid": "29134664",
    "citation": "Rita Assi et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.. American journal of hematology (2018 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29134664/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No efficacy data for CMML is present in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "29069007",
    "citation": "Yayue Gao et al. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.. Medicine (2017 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29069007/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 2,
    "cmml_patients": 2,
    "supporting_quotes": [
      "In both patients, the platelet counts returned to the normal within 1 week after eltrombopag therapy.",
      "The platelet count in case 1 patient remained stable at 141-200 \u00d7 10/L for 20 months with stopping therapy for 3 months.",
      "In case 2 patient, eltrombopag was stopped 1 month later. Her platelet count decreased to 41 \u00d7 10/L, but was stable at \u223c30 \u00d7 10/L for 3 months with platelet transfusion independency for 12 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Both patients with CMML and thrombocytopenia showed a rapid increase in platelet counts after eltrombopag treatment.  Case 1 maintained stable platelet counts for 20 months with a 3-month treatment interruption, and case 2 remained transfusion-independent for 12 months after a period of lower platelet counts following eltrombopag discontinuation.",
    "has_efficacy_data": true
  },
  {
    "pmid": "28905323",
    "citation": "Yukio Kobayashi et al. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.. International journal of hematology (2018 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28905323/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival metrics)  were found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28885734",
    "citation": "Sanam Loghavi et al. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.. Journal of cutaneous pathology (2017 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28885734/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We describe a 67-year-old man with a 3-year history of CMML"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study describes a single case of CMML with cutaneous involvement. No response rates or survival data were reported.  The patient had been on azacitidine with stable disease for three years before developing skin lesions and splenomegaly.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28760301",
    "citation": "Brittany Knick Ragon et al. The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.. Clinical lymphoma, myeloma & leukemia (2017 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28760301/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) on CMML treatment is provided in the abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28621841",
    "citation": "Amer M Zeidan et al. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.. Cancer (2017 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28621841/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 13,
    "total_patients": 1378,
    "cmml_patients": 1378,
    "supporting_quotes": [
      "Among 1378 older adults diagnosed with CMML, the median OS was 13 months",
      "In the primary matched analysis, with 225 HMA users diagnosed in 2007-2011 and 395 patients diagnosed in 2001-2003, the median OS times were 17 and 11 months, respectively"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study found a median overall survival of 13 months for all CMML patients.  In a matched cohort analysis, patients receiving hypomethylating agents (HMAs) had a median OS of 17 months compared to 11 months for those not receiving HMAs, representing a 28% reduction in the risk of death.",
    "has_efficacy_data": true
  },
  {
    "pmid": "28607470",
    "citation": "V Santini et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.. Leukemia (2018 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28607470/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain any specific clinical efficacy data (response rates or survival data) for decitabine in CMML treatment.  It only mentions the lack of effective treatments and the initiation of a phase 2 study.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28546581",
    "citation": "G Garcia-Manero et al. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u2a7d30% blasts.. Leukemia (2017 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28546581/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 113,
    "cmml_patients": null,
    "supporting_quotes": [
      "This phase 1b/2b trial (n=113) was designed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of panobinostat (PAN)+AZA (phase 1b) and evaluate the early efficacy and safety of PAN+AZA vs AZA monotherapy (phase 2b) in patients with higher-risk MDS, chronic myelomonocytic leukemia or oligoblastic acute myeloid leukemia with <30% blasts."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract states the study aimed to evaluate efficacy but doesn't provide specific response rates or survival data.  Only the total number of patients is explicitly given.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28535394",
    "citation": "M Leisch et al. Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.. Leukemia research (2017 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28535394/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 184,
    "cmml_patients": null,
    "supporting_quotes": [
      "We therefore retrospectively analyzed transfusion requirements and clinical outcomes of 184 patients with myloid neoplasms treated with azacitidine"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study focuses on transfusion requirements and alloimmunization,  not providing response rates or survival data related to azacitidine treatment efficacy in CMML.  Total patient number is the only efficacy-related metric extracted.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28486043",
    "citation": "Mikkael A Sekeres et al. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28486043/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain specific clinical efficacy data such as response rates or survival metrics.  It only describes the study's purpose and design.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28370097",
    "citation": "Ana Alfonso et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.. American journal of hematology (2017 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28370097/",
    "drug": "azacitidine",
    "complete_response": 41.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 75.0,
    "progression_free_survival_median": 14.0,
    "overall_survival_median": 24.0,
    "total_patients": 151,
    "cmml_patients": 151,
    "supporting_quotes": [
      "With a median follow-up of 17 months, overall response rate (ORR) was 75%, with 41% achieving complete response (CR).",
      "Median overall survival (OS) was 24 months (95%CI: 20-28) and event-free survival 14 months (95%CI: 11-17)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Hypomethylating agents showed an overall response rate of 75%, with a 41% complete response rate. Median overall survival was 24 months and median progression-free survival was 14 months.  Decitabine showed a significantly higher complete response rate (58.3%) compared to azacitidine (20.6%). Outcomes after HMA failure were poor, with a median OS of 7 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "28368509",
    "citation": "M T Voso et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.. Annals of oncology : official journal of the European Society for Medical Oncology (2017 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28368509/",
    "drug": "azacitidine",
    "complete_response": 24.0,
    "partial_response": 14.0,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 97,
    "cmml_patients": 8,
    "supporting_quotes": [
      "After a median of four cycles (range 1-11): 24% of patients achieved complete remission, 14% partial remission, 8% hematologic improvement, 32% had stable and 22% progressive disease.",
      "We conducted a phase II multicenter study to prospectively evaluate the feasibility of HSCT after treatment with AZA in 70 patients with a myelodysplastic syndrome (MDS), 19 with acute myeloid leukemia (AML), and 8 with chronic myelomonocytic leukemia (CMML)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports complete remission (CR) in 24% and partial remission (PR) in 14% of patients after a median of four cycles of azacitidine.  Overall response rate is not explicitly provided. No survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "28359286",
    "citation": "Florian Wolff et al. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.. Cell communication and signaling : CCS (2017 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28359286/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) for CMML treatment were found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28102729",
    "citation": "Jia Gu et al. Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.. Cancer biology & therapy (2017 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28102729/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We reported a 51-year-old man who had CMML with concomitant mutations in DNMT3A and FLT3-ITD."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study only reports on a single patient with CMML treated with decitabine and sorafenib. No response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "28024498",
    "citation": "Yue-Sheng Meng et al. [Reactivated Expression of MicroRNA-124 in Patients with Myelodysplastic Syndromes after Demethylating Therapy].. Zhongguo shi yan xue ye xue za zhi (2016 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28024498/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 35,
    "cmml_patients": null,
    "supporting_quotes": [
      "The expression levels of miR-124 in the MNC of 35 MDS patients and 10 healthy donors were detected with stem-loop quantitative real time polymerase chain reaction assay.",
      "This study also proved that expression of miR-124 was reactivated in 7 out of 18 MDS patients after treatment with low dose decitabine."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study mentions that miR-124 expression was reactivated in 7 out of 18 MDS patients after decitabine treatment.  However, no response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "27849645",
    "citation": "Ana Alfonso et al. Current management of patients with chronic myelomonocytic leukemia.. Current opinion in oncology (2017 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27849645/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract provides background information on CMML and its treatment, mentioning hypomethylating agents and allogeneic stem cell transplantation, but does not report specific clinical efficacy metrics such as response rates or survival data.",
    "has_efficacy_data": false
  },
  {
    "pmid": "27365372",
    "citation": "C A Moura et al. Chronic myelomonocytic leukemia mimicking hematologic systemic lupus erythematosus.. Lupus (2017 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27365372/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "The aim of this study was to describe a case of an elderly woman with thrombocytopenia and positivity of antibodies to anti-extractable nuclear antigens (anti-ENA) as initial manifestation of CMML mimicking SLE, and to present some clues that encourage the clinician to perform a bone marrow study in such a clinical scenario."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study presents a single case report of CMML mimicking SLE, providing no quantitative efficacy data on treatment response or survival.",
    "has_efficacy_data": false
  },
  {
    "pmid": "27353473",
    "citation": "Colombe Saillard et al. Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.. Hematological oncology (2017 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27353473/",
    "drug": "azacitidine",
    "complete_response": 100.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 100.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Treatment with 5-azacytidine led to the complete remission of both diseases."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In this single case report, treatment with 5-azacytidine resulted in a complete remission of both AITL and CMML.",
    "has_efficacy_data": true
  },
  {
    "pmid": "27268068",
    "citation": "Melita Kenealy et al. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).. Leukemia & lymphoma (2017 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27268068/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The provided abstract does not contain specific clinical efficacy data such as response rates or survival metrics for CMML patients.",
    "has_efficacy_data": false
  },
  {
    "pmid": "27185207",
    "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.. American journal of hematology (2016 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27185207/",
    "drug": "azacitidine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 35.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of \u223c30-40% and complete remission rates of \u223c7-17%",
      "The GFM model segregates patients into 3 groups ... with respective median survivals of 56 (low), 27.4 (intermediate), and 9.2 (high) months.",
      "The MMM is based on ... This model stratifies patients into four groups; high (\u22653 risk factors), intermediate-2 (2 risk factors), intermediate-1 (1 risk factor) and low (no risk factors), with median survivals of 16, 31, 59, and 97\u00a0months, respectively."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports overall response rates of 30-40% and complete remission rates of 7-17% for hypomethylating agents.  The GFM and MMM prognostic models provide overall survival median values ranging from 9.2 to 97 months depending on risk factors.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26922775",
    "citation": "Jean-Baptiste Fraison et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.. Leukemia research (2016 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26922775/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 55.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 22,
    "cmml_patients": null,
    "supporting_quotes": [
      "Response of AID to Azacitidine was observed in 19 patients (86%).",
      "Hematologic response was seen in 55% of the patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall hematologic response rate of 55% to Azacitidine in patients with autoimmune disorders associated with MDS/CMML.  No data on complete response, partial response, marrow complete response, progression-free survival, or overall survival was provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26860635",
    "citation": "Marjan Cruijsen et al. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2016 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26860635/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 30,
    "cmml_patients": 2,
    "supporting_quotes": [
      "Thirty patients were enrolled, including 11 with MDS, 2 with CMML, and 17 with AML.",
      "At a median follow-up of 443 days, the overall survival was 53%, relapse incidence was 27%, and nonrelapse mortality was 27%."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports overall survival of 53% at a median follow-up of 443 days (approximately 14.8 months), relapse incidence of 27%, and non-relapse mortality of 27%.  No response rates (CR, PR, mCR, ORR) or PFS data were provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26392142",
    "citation": "Takumi Matsumoto et al. A case of chronic myelomonocytic leukemia complicated with spondyloarthritis.. Modern rheumatology (2018 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26392142/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 64-year-old female patient, admitted to our hospital with buttock pain alternating left and right, was found to have sacroiliitis and spondylitis by contrast magnetic resonance imaging.",
      "Although arthritic symptoms and imaging findings initially improved by azacitidine, CMML was thereafter transformed into acute myeloid leukemia."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study presents a single case report of CMML.  While azacitidine showed initial improvement in arthritic symptoms, the CMML progressed to acute myeloid leukemia. No response rates or survival data were provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "26350487",
    "citation": "Ars\u00e8ne Mekinian et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.. Rheumatology (Oxford, England) (2016 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26350487/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 83.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 123,
    "cmml_patients": null,
    "supporting_quotes": [
      "In this study, 123 patients with MDS and SIADs were analysed.",
      "One hundred and eighteen (96%) SIAD patients were treated (91% with steroids), with an 83% response to first-line treatment, including 80% for steroids alone."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 83% to first-line treatment for systemic inflammatory and autoimmune diseases (SIADs) associated with myelodysplastic syndromes (MDS).  The response rate to steroids alone was 80%.  No overall survival or progression-free survival data is provided for CMML treatment efficacy.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26296092",
    "citation": "Eric Laille et al. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.. PloS one (2015)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26296092/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 59,
    "cmml_patients": null,
    "supporting_quotes": [
      "\"PK and/or PD data were available for 59 patients who were sequentially assigned to 1 of 4 extended CC-486 dosing schedules\"",
      "Patients who had a hematologic response had significantly greater methylation reductions than non-responding patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study shows that extended dosing of CC-486 leads to sustained epigenetic effects (DNA methylation reduction).  A correlation was found between methylation reduction and hematologic response, but specific response rates (CR, PR, ORR) or survival data are not provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "25822018",
    "citation": "Kristen Meldi et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.. The Journal of clinical investigation (2015 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25822018/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 40,
    "cmml_patients": 40,
    "supporting_quotes": [
      "Here, we examined baseline differences in mutations, DNA methylation, and gene expression in 40 CMML patients who were responsive or resistant to decitabine (DAC) in order to develop a molecular means of predicting response at diagnosis."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study identified 167 differentially methylated regions (DMRs) that distinguished responders from nonresponders to decitabine.  No overall response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "25735917",
    "citation": "St\u00e9phanie Harel et al. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.. Leukemia research (2015 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25735917/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": 8.33,
    "overall_response_rate": 19.4,
    "progression_free_survival_median": null,
    "overall_survival_median": 7.3,
    "total_patients": 36,
    "cmml_patients": null,
    "supporting_quotes": [
      "Seven (19.4%) patients were responders including 3 marrow CR (mCR), 2 stable disease (SD) with HI-E, 1 SD with HI-N and HI-P and 1 SD with HI-N.",
      "Median OS from onset of decitabine was 7.3 months",
      "Treatment with decitabine after azacitidine failure yielded modest ORR (19.4%) with short response duration and poor OS."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Decitabine treatment after azacitidine failure in high-risk MDS and CMML patients showed a modest overall response rate (ORR) of 19.4%, with a median overall survival (OS) of 7.3 months.  Responses were short-lived.  The mCR rate was 8.33% (3/36).",
    "has_efficacy_data": true
  },
  {
    "pmid": "25555161",
    "citation": "M M Patnaik et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.. Blood cancer journal (2015 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25555161/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 40.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 261,
    "cmml_patients": 261,
    "supporting_quotes": [
      "'In multivariable analysis, lower HB (P=0.01), higher circulating blast % (P=0.002), ASXL1 (P=0.0007) and SRSF2 mutations (P=0.008) and Mayo-French cytogenetic stratification (P=0.04) negatively impacted survival.'",
      "'Seventy-five (29%) patients received hypomethylating agents (HMA), with the median number of cycles being 5, and the median duration of therapy being 5 months.'",
      "The over-all response rate was 40% for azacitidine and 30% for decitabine.'",
      "'Fifty-three (24%) patients underwent an allogeneic hematopoietic stem cell transplant (AHSCT), with a response rate of 56% and a non-relapse mortality of 19%.'"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 40% for azacitidine and 30% for decitabine in CMML patients treated with hypomethylating agents.  Allogeneic hematopoietic stem cell transplant showed a 56% response rate.  No median survival times were provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "25444072",
    "citation": "Y Beguin et al. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.. Acta clinica Belgica (2015 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25444072/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 41.4,
    "progression_free_survival_median": null,
    "overall_survival_median": 40.8,
    "total_patients": 49,
    "cmml_patients": 2,
    "supporting_quotes": [
      "Among MDS and CMML patients (n\u200a=\u200a29), 41\u00b74% had CR, PR, or HI, 41\u00b74% had SD, and 17\u00b72% had TF.",
      "Median (95% confidence interval) OS was 490 (326-555) days; 1-year OS estimate was 0\u00b7571 (0\u00b7422-0\u00b7696)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In a real-life setting, azacitidine showed an overall response rate of 41.4% among MDS and CMML patients.  Median overall survival was 40.8 months (490 days).",
    "has_efficacy_data": true
  },
  {
    "pmid": "25317956",
    "citation": "S Meers et al. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.. Current medical research and opinion (2015 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25317956/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 175,
    "cmml_patients": 7,
    "supporting_quotes": [
      "Between January 2013 and June 2014, 63 physicians (53 Belgian hospitals) recruited 175 patients.",
      "In total, 163 patient dossiers were approved by Celgene (120 MDS, 36 AML, and 7 CMML)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study focuses on access to azacitidine, not on clinical efficacy.  Patient numbers for CMML and total patients are provided, but no response rates or survival data are reported.",
    "has_efficacy_data": false
  },
  {
    "pmid": "25129095",
    "citation": "Masahiro Manabe et al. [Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report].. Gan to kagaku ryoho. Cancer & chemotherapy (2014 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25129095/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 7 1-year-old man was admitted to our hospital with leukocytosis and anemia.",
      "Chronic myelomonocytic leukemia (CMML)harboring del(20q)was diagnosed by peripheral blood examination and bone marrow aspiration.",
      "The patient was subsequently treated with azacitidine, which resulted in rapid disappearance of monocytosis and resolved his dependency on red cell transfusion."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The case report describes a single CMML patient with del(20q) who experienced a clinical response to azacitidine, characterized by the resolution of monocytosis and transfusion dependency.  No quantitative response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "24836762",
    "citation": "Cecile Bally et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.. Leukemia research (2014 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24836762/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 21.2,
    "total_patients": 62,
    "cmml_patients": null,
    "supporting_quotes": [
      "TP53 mutations had no significant impact on response or complete response to AZA (p=0.60 and p=0.26, respectively).",
      "By univariate analysis, OS was negatively influenced by the presence of TP53 mutation (median OS 12.4 months versus 23.7 months, p<10(-4)), abnormal cytogenetics (median OS 14.4 months vs 33 months, p=0.02) complex cytogenetics (median OS 12.7 months versus 23.7 months, p=0.0005), and a diagnosis of AML (median 14.5 months vs 21.2 months for MDS or CMML, p=0.02)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study found no significant impact of TP53 mutations on response to azacitidine.  Univariate analysis showed that overall survival (OS) was negatively impacted by TP53 mutations (median OS 12.4 months vs 23.7 months), with a median OS of 21.2 months observed for patients with MDS or CMML.",
    "has_efficacy_data": true
  },
  {
    "pmid": "24678397",
    "citation": "Andrea Tendas et al. Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach.. Mediterranean journal of hematology and infectious diseases (2014)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24678397/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 70.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 10,
    "cmml_patients": 10,
    "supporting_quotes": [
      "The overall response rate of 70% was achieved without remarkable toxicities",
      "At our institution, between 2010 and 2012, we have treated with azacitidine 10 CMML patients",
      "With a median follow-up of 12,5 (2-27) months, 6 patients are alive, and 4 of them continue to receive the treatment; the median survival from the start of therapy was not reached."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine demonstrated a 70% overall response rate in 10 CMML patients.  Median survival was not reached at a median follow-up of 12.5 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "24522248",
    "citation": "Lisa Pleyer et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.. Leukemia research (2014 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24522248/",
    "drug": "azacitidine",
    "complete_response": 22.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 70.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 27.7,
    "total_patients": 48,
    "cmml_patients": 48,
    "supporting_quotes": [
      "Overall response rates were high (70% according to IWG-criteria, including 22% complete responses).",
      "Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p=0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p=0.072, median OS 27.7 vs. 6.2 months)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine showed a 70% overall response rate, including a 22% complete response rate. Matched-pair analyses suggested a trend towards improved two-year survival and longer overall survival (median 27.7 months) compared to other treatments.",
    "has_efficacy_data": true
  },
  {
    "pmid": "24270737",
    "citation": "H Yang et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.. Leukemia (2014 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24270737/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 124,
    "cmml_patients": null,
    "supporting_quotes": [
      "We studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) mRNA in CD34+ cells from myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) patients (N=124)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study focuses on gene expression changes (PD-L1, PD-L2, PD-1, CTLA4) in response to hypomethylating agents in MDS, CMML, and AML.  It notes that patients resistant to therapy had higher gene expression increases, suggesting a potential role for PD-1 signaling in resistance.  No response rates or survival data are reported.",
    "has_efficacy_data": false
  },
  {
    "pmid": "23963888",
    "citation": "Sameer A Parikh et al. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.. American journal of hematology (2013 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23963888/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 18.5,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "The Mayo prognostic model classified CMML patients into three risk groups based on: increased absolute monocyte count, presence of circulating blasts, hemoglobin <10 gm/dL and platelets <100\u2009\u00d7\u200910\u2079/L. The median survival was 32 months, 18.5 months and 10 months in the low, intermediate, and high-risk groups, respectively.",
      "After a median follow-up of 2.5 years, survival ranged from not reached in the low-risk group to 14.4 months in the high-risk group."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The Mayo model shows median survival times of 32, 18.5, and 10 months for low, intermediate, and high-risk CMML patients, respectively.  The GFM model shows survival ranging from not reached to 14.4 months in high-risk patients after a 2.5 year follow-up.  No response rates are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "23625339",
    "citation": "T Menter et al. Development of an Epstein-Barr virus-associated lymphoproliferative disorder in a patient treated with azacitidine for chronic myelomonocytic leukaemia.. Hematological oncology (2014 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23625339/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "A 78-year-old female patient was diagnosed with CMML in January 2012, and treatment with azacitidine was initiated, which lasted for five cycles from February until June 2012."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports a single case of CMML treated with azacitidine.  No response rates or survival data are provided. The patient died due to complications from an Epstein-Barr virus-associated lymphoproliferative disorder.",
    "has_efficacy_data": false
  },
  {
    "pmid": "23602358",
    "citation": "Ulrich Germing et al. How to treat patients with CMML?. Leukemia research (2013 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23602358/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) were found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "23453287",
    "citation": "Antonio Almeida Modifying disease in CMML: who responds to Azacitidine?. Leukemia research (2013 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23453287/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival metrics) were found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "23415110",
    "citation": "Lionel Ad\u00e8s et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.. Leukemia research (2013 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23415110/",
    "drug": "azacitidine",
    "complete_response": 17.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 43.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 29.0,
    "total_patients": 76,
    "cmml_patients": 76,
    "supporting_quotes": [
      "Thirty-three patients (43%) achieved a response according to IWG 2006 criteria, including 13 complete remissions (17%).",
      "Median survival was 29 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine showed an overall response rate of 43% in 76 CMML patients, with a 17% complete remission rate. Median overall survival was 29 months.  The study notes that efficacy in advanced CMML needs further confirmation.",
    "has_efficacy_data": true
  },
  {
    "pmid": "23262795",
    "citation": "Jun Ho Yi et al. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.. Annals of hematology (2013 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23262795/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 26.4,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 61,
    "cmml_patients": null,
    "supporting_quotes": [
      "Best response was noted in 14 patients (26.4 %) out of 53 evaluated patients including 12 CR and two PR with median follow-up of 21.6 months",
      "A total of 61 MDS/CMML patients treated with decitabine were evaluated"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reported an overall response rate of 26.4% (14/53 patients) to decitabine treatment in MDS/CMML patients.  The response included 12 complete responses and 2 partial responses.  Median follow-up was 21.6 months.  No specific survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "23079062",
    "citation": "Lionel Ad\u00e8s et al. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.. Seminars in hematology (2012 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23079062/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Notably, in a phase III randomized trial, AZA significantly prolonged overall survival (OS) compared to conventional care regimens, in all cytogenetic subgroups."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract mentions that azacitidine significantly prolonged overall survival in a phase III trial compared to conventional care regimens for higher-risk MDS.  However, no specific response rates or survival times are provided for any patient population, including CMML patients.",
    "has_efficacy_data": false
  },
  {
    "pmid": "22937326",
    "citation": "Peter Rohon et al. Treatment of chronic myelomonocytic leukemia with 5-azacytidine: case reports.. Case reports in hematology (2012)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22937326/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": 33.3,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 3,
    "cmml_patients": 3,
    "supporting_quotes": [
      "In this paper our experience with 3 CMML patients treated with AZA is described.",
      "In one patient transfusion independency was observed after 4 treatment cycles; in one case a partial response was recorded, but a progression to acute myeloid leukemia (AML) after 13 AZA cycles has appeared."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "Out of 3 CMML patients treated with 5-azacytidine, one achieved transfusion independence, and one had a partial response.  No overall response rate, progression-free survival, or overall survival data was provided. One patient progressed to AML.",
    "has_efficacy_data": true
  },
  {
    "pmid": "22622173",
    "citation": "Antonio M Almeida et al. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.. Leukemia research (2012 Sep)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22622173/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "No clinical efficacy data (response rates or survival data) on CMML treatment was found in the provided abstract.",
    "has_efficacy_data": false
  },
  {
    "pmid": "22615103",
    "citation": "Sameer A Parikh et al. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.. American journal of hematology (2012 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22615103/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "abstract",
    "extraction_confidence": 0,
    "efficacy_summary": "The abstract summarizes the diagnosis, risk stratification, and management of CMML but does not provide any specific clinical efficacy data such as response rates or survival metrics from clinical trials.",
    "has_efficacy_data": false
  },
  {
    "pmid": "22607959",
    "citation": "Michael Thorpe et al. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review.. Leukemia research (2012 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22607959/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 60.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 20,
    "total_patients": 10,
    "cmml_patients": 10,
    "supporting_quotes": [
      "We present the outcome of ten patients diagnosed with CMML and treated with AZA in our institutions between 2005 and 2010.",
      "The overall response rate was 60%.",
      "Responses were obtained in 2/3 of the patients with proliferative CMML.",
      "The median survival from start of therapy was 20 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 60% in 10 CMML patients treated with AZA.  Median overall survival was 20 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "22555082",
    "citation": "Hannah B Trickett et al. Azacitidine-associated Sweet's syndrome.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2012 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22555082/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 2,
    "cmml_patients": 1,
    "supporting_quotes": [
      "In one of two cases of probable azacitidine-related Sweet's syndrome reported here, a 64-year-old man with myelodysplastic syndrome (MDS) developed a severe erythematous and nodular rash with peeling on his arms, legs, and face after receiving the drug (75 mg/m(2) subcutaneously daily) for three days; the second case involved a 67-year-old man with chronic myelomonocytic leukemia (CMML) who experienced a similar skin rash, as well as chills and an elevated body temperature, after five days of treatment with azacitidine."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports on two cases of Sweet's syndrome associated with azacitidine treatment.  One patient had CMML, the other MDS.  The paper focuses on the adverse event (Sweet's syndrome) and its treatment with corticosteroids, not on the efficacy of azacitidine in treating CMML or MDS.",
    "has_efficacy_data": false
  },
  {
    "pmid": "22550562",
    "citation": "Elena Elli et al. A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature.. Mediterranean journal of hematology and infectious diseases (2012)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22550562/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "However, phase 2 and 3 studies that assessed these agents in MDS, have included only a small number of patients with CMML, and there are just a few specific reports on CMML patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 50,
    "efficacy_summary": "The abstract mentions that phase 2 and 3 studies on hypomethylating agents included only a small number of CMML patients, and there are few specific reports.  No specific efficacy data (response rates or survival data) is provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "22280532",
    "citation": "Massimo Breccia et al. 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.. Leukemia & lymphoma (2012 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22280532/",
    "drug": "azacitidine",
    "complete_response": 18.0,
    "partial_response": 18.0,
    "marrow_complete_response": null,
    "overall_response_rate": 36.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 16.4,
    "total_patients": 38,
    "cmml_patients": 4,
    "supporting_quotes": [
      "after the first four cycles we detected complete remission in seven patients (CR, 18%), improvement of bone marrow dysplasia and reduction of blast percentage in seven patients (partial response, 18%), stable disease in 20 patients (53%) and progression to acute leukemia in four patients (10%)",
      "Median overall survival for all patients treated was 16.4 months",
      "four patients with chronic myelomonocytic leukemia type 2 (CMML-2)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In this study of 38 MDS patients (including 4 with CMML), azacitidine treatment resulted in a 18% complete response rate and a 18% partial response rate, leading to a 36% overall response rate. Median overall survival was 16.4 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "21981697",
    "citation": "Lieke H van der Helm et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.. British journal of haematology (2011 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21981697/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 50.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 13.0,
    "total_patients": 90,
    "cmml_patients": null,
    "supporting_quotes": [
      "The overall response rate (complete/partial/haematological improvement) was 57% in low risk MDS, 53% in high risk MDS, 50% in CMML, and 39% in AML patients.",
      "Median overall survival (OS) was 13\u00b70 (9\u00b78-16\u00b72) months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine demonstrated an overall response rate of 50% in CMML patients, with a median overall survival of 13 months.  Specific response rates (CR, PR, mCR) are not provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "21828134",
    "citation": "Thorsten Braun et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.. Blood (2011 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21828134/",
    "drug": "azacitidine",
    "complete_response": 10.0,
    "partial_response": null,
    "marrow_complete_response": 21.0,
    "overall_response_rate": 38.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 39,
    "cmml_patients": 39,
    "supporting_quotes": [
      "Overall response rate was 38% with 4 complete responses (10%), 8 marrow responses (21%), and 3 stable diseases with hematologic improvement (8%).",
      "With a median follow-up of 23 months, overall survival was 48% at 2 years."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 38% to decitabine in 39 patients with advanced CMML.  Complete responses were observed in 10% of patients and marrow responses in 21%. Overall survival at 2 years was 48%.",
    "has_efficacy_data": true
  },
  {
    "pmid": "21656746",
    "citation": "Rubens Costa et al. Activity of azacitidine in chronic myelomonocytic leukemia.. Cancer (2011 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21656746/",
    "drug": "azacitidine",
    "complete_response": 11.0,
    "partial_response": 3.0,
    "marrow_complete_response": null,
    "overall_response_rate": 39.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 12.0,
    "total_patients": 38,
    "cmml_patients": 38,
    "supporting_quotes": [
      "The overall response rate was 39% (14 of 36); complete response (CR) rate was 11% (4 of 36); partial response (PR) rate was 3% (1 of 36); hematologic improvement (HI) was 25% (9 of 36).",
      "The median overall survival was 12 months.",
      "There was a statistically significant overall survival advantage in responders compared with nonresponders: 15.5 months versus 9 months, respectively (P = .04)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Azacitidine demonstrated an overall response rate of 39% in CMML patients, with 11% achieving complete response and 3% partial response. Median overall survival was 12 months, significantly longer (15.5 months) for responders compared to non-responders (9 months).",
    "has_efficacy_data": true
  },
  {
    "pmid": "21625315",
    "citation": "M Greco et al. 5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature.. Mediterranean journal of hematology and infectious diseases (2011)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21625315/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": 66.7,
    "marrow_complete_response": null,
    "overall_response_rate": 66.7,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 3,
    "cmml_patients": 3,
    "supporting_quotes": [
      "Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Two out of three CMML patients achieved a partial response after four cycles of azacitidine treatment.  These patients remained in partial response for at least 29 and 30 cycles.",
    "has_efficacy_data": true
  },
  {
    "pmid": "21576646",
    "citation": "Guillermo Garcia-Manero et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21576646/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 35.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 41,
    "cmml_patients": 4,
    "supporting_quotes": [
      "Overall response rate (i.e., complete remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in previously untreated patients.",
      "Overall, 41 patients received SC and oral azacitidine (MDSs, n = 29; CMML, n = 4; AML, n = 8)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 35% in previously treated patients and 73% in previously untreated patients with MDS and CMML.  No data on complete response, partial response, marrow complete response, progression-free survival, or overall survival was provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "21537084",
    "citation": "Romain Aucagne et al. Transcription intermediary factor 1\u03b3 is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.. The Journal of clinical investigation (2011 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21537084/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "TIF1\u03b3 was almost undetectable in leukemic cells of 35% of CMML patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study found that TIF1\u03b3 was undetectable in 35% of CMML patients.  No response rates or survival data were provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "21387357",
    "citation": "Murat Ozbalak et al. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.. Hematological oncology (2012 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21387357/",
    "drug": "azacitidine",
    "complete_response": 12.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 36.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 25,
    "cmml_patients": null,
    "supporting_quotes": [
      "Complete response (CR) rate was observed in three of the 25 'real life' patients (12%) with a median duration of CR of 5 months (4-6 months).",
      "Seven patients (28%) had mono- or bi-lineage haematologic improvement and 15 patients (60%) showed neither morphologic nor haematologic response."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed a 12% complete response rate and a 28% rate of mono- or bi-lineage hematologic improvement among 25 patients with MDS, CMML, or AML treated with azacitidine. The overall response rate is calculated as 36% (12% CR + 28% hematologic improvement). No overall survival or progression-free survival data was explicitly provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "20507806",
    "citation": "R Edlin et al. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.. Health technology assessment (Winchester, England) (2010 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/20507806/",
    "drug": "azacitidine",
    "complete_response": 17.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 24.5,
    "total_patients": 358,
    "cmml_patients": null,
    "supporting_quotes": [
      "the median overall survival was 24.5 months on aza, compared with 15.0 months in the CCR group (p = 0.0001)",
      "the response rates were low (complete remission 17% aza versus 8% CCR);",
      "the median time to transformation to AML was greater in the aza group (17.8 versus 11.5 months; p < 0.0001)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine demonstrated improved overall survival (24.5 months vs 15.0 months in the control group) and delayed time to AML transformation (17.8 months vs 11.5 months). Complete response rates were low (17% in the azacitidine group vs 8% in the control group).  The number of CMML patients was not explicitly stated.",
    "has_efficacy_data": true
  },
  {
    "pmid": "20451404",
    "citation": "John F Seymour et al. Effects of azacitidine compared with conventional care regimens in elderly (\u2265 75 years) patients with higher-risk myelodysplastic syndromes.. Critical reviews in oncology/hematology (2010 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/20451404/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 87,
    "cmml_patients": null,
    "supporting_quotes": [
      "This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated overall survival (OS) and tolerability in the subset of 87 elderly (\u2265 75 years) patients with higher-risk MDS (FAB: RAEB, RAEB-t, CMML and IPSS: Int-2 or High) from the AZA-001 trial.",
      "AZA significantly improved OS vs CCR (HR: 0.48 [95%CI: 0.26, 0.89]; p=0.0193) and 2-year OS rates were 55% vs 15% (p<0.001), respectively."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study shows a significant improvement in overall survival (OS) for azacitidine compared to conventional care regimens (CCR) in elderly patients with higher-risk MDS, including a subset of CMML patients.  The exact number of CMML patients is not specified, and no response rates were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "20064151",
    "citation": "Bart L Scott et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.. British journal of haematology (2010 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/20064151/",
    "drug": "azacitidine",
    "complete_response": 28.1,
    "partial_response": 6.3,
    "marrow_complete_response": 31.3,
    "overall_response_rate": 72.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 32,
    "cmml_patients": null,
    "supporting_quotes": [
      "At 3 months, nine patients had achieved complete response (CR), two had partial response, 10 had marrow CRs, seven had stable disease, two patients had haematological improvement without marrow response and two patients had disease progression.",
      "The overall response rate was 72%; median duration of response was not reached at 2 years."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 72% at 3 months, with 28.1% achieving complete response, 6.3% partial response, and 31.3% marrow complete response.  Median duration of response was not reached at 2 years.  Specific numbers for CMML patients are not provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "19911860",
    "citation": "Gillian M Keating Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.. Drugs (2009)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/19911860/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "In addition, azacitidine is associated with a lower risk of AML progression and higher rates of complete remission, partial remission, haematological improvement and red blood cell (RBC) transfusion independence."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 50,
    "efficacy_summary": "The abstract mentions improved outcomes like higher rates of complete and partial remission and reduced AML progression risk with azacitidine compared to conventional care. However, no specific numerical data on response rates or survival are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "19638460",
    "citation": "Maria Teresa Voso et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.. Clinical cancer research : an official journal of the American Association for Cancer Research (2009 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/19638460/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 30.7,
    "progression_free_survival_median": null,
    "overall_survival_median": 14.4,
    "total_patients": 62,
    "cmml_patients": 4,
    "supporting_quotes": [
      "Of 26 patients who completed eight cycles, 30.7% obtained complete or partial remission, 15.4% had a major hematologic improvement, whereas 38.5% showed stable disease.",
      "The median overall survival was 14.4 months.",
      "We enrolled 62 patients with MDS (refractory anemia with excess blasts, 39 patients; refractory anemia with excess blasts in transformation, 19 patients; and chronic myelomanocytic leukemia (CMML), 4 patients)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In a study of 62 patients with higher-risk MDS (including 4 with CMML), the combination of 5-AZA and VPA showed a 30.7% overall response rate (complete or partial remission) among 26 patients completing eight cycles. Median overall survival was 14.4 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "19430863",
    "citation": "Faheem Ahmed et al. Therapy related CMML: a case report and review of the literature.. International journal of hematology (2009 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/19430863/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": 1,
    "supporting_quotes": [
      "She received 4 cycles of azacitidine and proceeded with allogeneic bone marrow transplant.",
      "This is the first a case of t-CMML reported in a liver transplant recipient."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The case report details treatment of one t-CMML patient with azacitidine followed by allogeneic bone marrow transplant. No response rates or survival data are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "18179966",
    "citation": "Elizabeth A Griffiths et al. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.. Seminars in hematology (2008 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/18179966/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 30.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "These agents were developed based upon an understanding of the importance of epigenetic changes in malignancy, and they have been evaluated in randomized clinical trials, which demonstrate response rates between 20% and 40% in patients for whom no previous standard of care was available."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract reports overall response rates between 20% and 40% for 5-azacitidine and 5-aza-2'-deoxyazacytidine in clinical trials for MDS and CMML patients without prior standard treatment.  No specific data for CMML alone or on survival is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "17881052",
    "citation": "P W Wijermans et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).. Leukemia research (2008 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17881052/",
    "drug": "azacitidine",
    "complete_response": 14.0,
    "partial_response": 11.0,
    "marrow_complete_response": null,
    "overall_response_rate": 25.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 31,
    "cmml_patients": 31,
    "supporting_quotes": [
      "The ORR was 25% (14% CR+11% PR)",
      "A total of 31 patients diagnosed with CMML are included in this review"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Decitabine demonstrated an overall response rate of 25% in 31 CMML patients, with 14% achieving complete response and 11% achieving partial response.  No survival data was reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "17219444",
    "citation": "Ahmed Aribi et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.. Cancer (2007 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17219444/",
    "drug": "azacitidine",
    "complete_response": 58.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 69.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 19,
    "total_patients": 19,
    "cmml_patients": 19,
    "supporting_quotes": [
      "Overall, 11 patients (58%) achieved complete response (CR) and 2 (11%) had hematologic improvement (HI), for an overall response rate of 69% according to the modified International Working Group (IWG) criteria.",
      "Median survival was 19 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Decitabine demonstrated a 69% overall response rate in 19 CMML patients, with 58% achieving complete response. Median survival was 19 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "16955510",
    "citation": "Alfonso Quintas-Cardama et al. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.. Cancer (2006 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/16955510/",
    "drug": "azacitidine",
    "complete_response": 11.0,
    "partial_response": 16.0,
    "marrow_complete_response": null,
    "overall_response_rate": 41.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 44,
    "cmml_patients": 32,
    "supporting_quotes": [
      "Overall, 5 (11%) patients achieved complete response (CR), 7 (16%) had a partial response (PR), and 6 (14%) had hematologic improvement (HI), for an overall response rate of 41%.",
      "Adults with a diagnosis of MDS (n = 12) and CMML (n = 32) received 9-NC 2 mg/m(2) orally daily 5 days a week, every 4 to 6 weeks."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study showed an overall response rate of 41% in patients with MDS and CMML treated with 9-NC, with 11% achieving complete response and 16% achieving partial response.  No survival data was reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "16882708",
    "citation": "Hagop Kantarjian et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.. Blood (2007 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/16882708/",
    "drug": "azacitidine",
    "complete_response": 34.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 73.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 95,
    "cmml_patients": 18,
    "supporting_quotes": [
      "Overall, 32 patients (34%) achieved a complete response (CR), and 69 (73%) had an objective response by the new modified International Working Group criteria.",
      "The 5-day intravenous schedule, which had the highest dose-intensity, was selected as optimal; the CR rate in that arm was 39%, compared with 21% in the 5-day subcutaneous arm and 24% in the 10-day intravenous arm (P < .05).",
      "Ninety-five patients were treated (77 with MDS, and 18 with CMML)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 73% with a complete response rate of 34% across all treatment arms.  The 5-day intravenous schedule demonstrated superior efficacy with a 39% complete response rate.",
    "has_efficacy_data": true
  },
  {
    "pmid": "12599231",
    "citation": "Marcos de Lima et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.. Cancer (2003 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/12599231/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 26.0,
    "progression_free_survival_median": 8.9,
    "overall_survival_median": 17.2,
    "total_patients": 23,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Twenty-one patients were engrafted and achieved disease remission.",
      "At a median of 3.3 years posttransplantation, 26% of patients (40% of patients with AML) were alive and disease free.",
      "The median survival for the group was 17.2 months, and the disease free survival for the group was 8.9 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed a 26% overall response rate, with a median overall survival of 17.2 months and a median disease-free survival of 8.9 months. Only one patient with CMML participated in the study.",
    "has_efficacy_data": true
  },
  {
    "pmid": "9922042",
    "citation": "M Beran et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.. Leukemia & lymphoma (1998 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/9922042/",
    "drug": "azacitidine",
    "complete_response": 27.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 10.5,
    "total_patients": 60,
    "cmml_patients": 30,
    "supporting_quotes": [
      "Nineteen patients (31%) achieved a complete response (CR). A CR was achieved in 11 of 30 patients with MDS (37%) and in eight of 30 with CMML (27%).",
      "With a median follow-up duration of 31 months, the 12 month survival rate was 38%, median survival time 10.5 months, and median remission duration 7.5 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Topotecan showed a 27% complete response rate in CMML patients.  Median overall survival was 10.5 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "8839838",
    "citation": "M Beran et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.. Blood (1996 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/8839838/",
    "drug": "azacitidine",
    "complete_response": 28.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 41.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 10.5,
    "total_patients": 47,
    "cmml_patients": 25,
    "supporting_quotes": [
      "Thirteen patients (28%) achieved a complete response (CR) and six (13%) had hematologic improvement.",
      "A CR was achieved in six of 22 patients with MDS (27%) and in seven of 25 with CMML (28%).",
      "With a median follow-up duration of 8 months, the 12-month survival rate was 38%, median survival time 10.5 months, and median remission duration 7.5 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Topotecan showed a 28% complete response rate overall, with similar rates in MDS and CMML patients.  The median overall survival was 10.5 months.",
    "has_efficacy_data": true
  }
]